Terminology Service for NFDI4Health
All terms in NCIT
| Label | Id | Description |
|---|---|---|
| How Big a Problem is Bloody Stools | NCIT_C125034 | [A question about an individual's assessment of how big a problem bloody stools have been.] |
| How Big a Problem is Abdominal, Pelvic, or Rectal Pain | NCIT_C125035 | [A question about an individual's assessment of how big a problem abdominal, pelvic, or rectal pain has been.] |
| Overall How Big a Problem Have Your Bowel Habits Been | NCIT_C125036 | [A question about an individual's overall assessment of how big a problem their bowel habits have been.] |
| Vaginal Cancer pT3 TNM Finding v8 | NCIT_C139649 | [Vaginal cancer with tumor extending to the pelvic sidewall and/or involving the lower third of the vagina and/or causing hydronephrosis or nonfunctioning kidney. Pelvic sidewall is defined as the muscle, fascia, neurovascular structures, or skeletal portions of the bony pelvis. (from AJCC 8th Ed.)] |
| Vaginal Cancer Pathologic Primary Tumor TNM Finding v8 | NCIT_C139640 | [A pathologic finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system as they pertain to staging of the primary tumor. The definitions of the T categories correspond to the stages accepted by FIGO. (from AJCC 8th Ed.)] |
| Synthetic Melanoma-Associated Antigens Vaccine | NCIT_C48639 | [A cancer vaccine containing synthetic epitope peptides derived from melanoma tumor-associated antigens (TAAs), including melanoma-melanocyte antigen gp100(280-288), melanoma-associated antigen tyrosinase(1-9), and melanoma-associated antigen melan-A(27-35). Upon administration, synthetic melanoma-associated antigens vaccine may stimulate a cytotoxic T-lymphocyte immune response against melanoma cells that express TAAs which share epitopes with the vaccine epitope peptides, resulting in tumor cell lysis.] |
| Vaginal Cancer pT1b TNM Finding v8 | NCIT_C139645 | [Vaginal cancer with tumor confined to the vagina, measuring more than 2.0 cm. (from AJCC 8th Ed.)] |
| Vaginal Cancer pT1 TNM Finding v8 | NCIT_C139643 | [Vaginal cancer with tumor confined to the vagina. (from AJCC 8th Ed.)] |
| Vaginal Cancer pT2 TNM Finding v8 | NCIT_C139646 | [Vaginal cancer with tumor invading paravaginal tissues but not to pelvic sidewall. (from AJCC 8th Ed.)] |
| Vaginal Cancer pT2a TNM Finding v8 | NCIT_C139647 | [Vaginal cancer with tumor invading paravaginal tissues but not to pelvic wall, measuring 2.0 cm or less. (from AJCC 8th Ed.)] |
| Vaginal Cancer pT2b TNM Finding v8 | NCIT_C139648 | [Vaginal cancer with tumor invading paravaginal tissues but not to pelvic wall, measuring more than 2.0 cm. (from AJCC 8th Ed.)] |
| MSCV (MGMTP140K) Retroviral Vector-Transduced CD34+ Autologous PBSC | NCIT_C48635 | [CD34+ peripheral blood stem cells (PBSC) isolated from patient with hematopoietic cell tumor, and transfected with murine stem cell virus retroviral vector encoding a mutant version of the human DNA repair protein O6-alkylguanine-DNA methyltransferase (MGMT). This mutant MGMT protein, MGMTP140K, is resistant to the O6-benzylguanine (BG), an inhibitor of the wild type MGMT. Introduction of these transfected autologous PBSCs back to the patient, may stimulate the expression of the O6 BG resistant mutant MGMT protein, which when used in combination with O6-alkylating drugs could protect the hematopoietic system against the hematopoietic toxicity of chemotherapeutic agents.] |
| Vaginal Cancer pTX TNM Finding v8 | NCIT_C139641 | [Vaginal cancer in which the primary tumor cannot be assessed. (from AJCC 8th Ed.)] |
| Lenvatinib Mesylate | NCIT_C48636 | [A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.] |
| Vaginal Cancer pT0 TNM Finding v8 | NCIT_C139642 | [Vaginal cancer with no evidence of primary tumor. (from AJCC 8th Ed.)] |
| 851B Gel | NCIT_C48637 | [A topical gel containing a peptide derived from the human papillomavirus (HPV). Application of 851B gel may stimulate the host immune system to trigger a cytotoxic T-lymphocyte response to cells that express HPV.] |
| Recombinant Vaccinia-Multiepitope Melanoma Peptides-B7.1-B7.2 Vaccine | NCIT_C48638 | [A cancer vaccine consisting of an inactivated recombinant vaccinia virus encoding epitope peptides derived from melanoma-related HLA-A2-restricted tumor-associated antigens (TAAs), including Melan-A(27-35), gp100(280-288) and tyrosinase(1-9), and two co-stimulatory B7 proteins, B7.1 (CD80) and B7.2 (CD86). Upon administration, recombinant vaccinia-multiepitope melanoma peptides-B7.1-B7.2 vaccine may stimulate a cytotoxic T-lymphocyte response against melanoma cells that express TAAs which share epitopes with the epitope peptides expressed by the vaccine viral vector, resulting in tumor cell lysis; vaccine viral vector-expressed co-stimulatory proteins B7.1 and B7.2 may enhance the cytotoxic T-lymphocyte immune response to the TAAs.] |
| Vaginal Cancer pT1a TNM Finding v8 | NCIT_C139644 | [Vaginal cancer with tumor confined to the vagina, measuring 2.0 cm or less. (from AJCC 8th Ed.)] |
| Vaginal Cancer Pathologic TNM Finding v8 | NCIT_C139637 | [A pathologic finding about one or more characteristics of vaginal cancer, following the rules of the TNM AJCC v8 classification system.] |
| Gross Pathology Result | NCIT_C125008 | [The outcome of a gross, or macroscopic, pathologic examination.] |